IN2014DN08089A - - Google Patents

Info

Publication number
IN2014DN08089A
IN2014DN08089A IN8089DEN2014A IN2014DN08089A IN 2014DN08089 A IN2014DN08089 A IN 2014DN08089A IN 8089DEN2014 A IN8089DEN2014 A IN 8089DEN2014A IN 2014DN08089 A IN2014DN08089 A IN 2014DN08089A
Authority
IN
India
Prior art keywords
fatty acids
fish oil
progestogen
dha
epa
Prior art date
Application number
Inventor
Ilona Kaspar
Volker Krüger
Doris Röthlein
Martin Wolf
Jürgen Schmitt
Original Assignee
Braun Melsungen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braun Melsungen Ag filed Critical Braun Melsungen Ag
Publication of IN2014DN08089A publication Critical patent/IN2014DN08089A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a hormone containing oil in water emulsion for parenteral administration comprising a) progestogen and/or estrogen and b) fish oil triglycerides wherein the fish oil triglyceride consists of glycerol which is esterified with fatty acids wherein said fatty acids comprise eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in an amount of at least 45 % by weight of said fatty acids.
IN8089DEN2014 2012-02-29 2013-02-25 IN2014DN08089A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12157546 2012-02-29
PCT/EP2013/053686 WO2013127728A1 (en) 2012-02-29 2013-02-25 Hormone containing emulsion

Publications (1)

Publication Number Publication Date
IN2014DN08089A true IN2014DN08089A (en) 2015-05-01

Family

ID=47748635

Family Applications (2)

Application Number Title Priority Date Filing Date
IN8089DEN2014 IN2014DN08089A (en) 2012-02-29 2013-02-25
IN8088DEN2014 IN2014DN08088A (en) 2012-02-29 2013-02-25

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN8088DEN2014 IN2014DN08088A (en) 2012-02-29 2013-02-25

Country Status (16)

Country Link
US (2) US20150018320A1 (en)
EP (2) EP2819650A1 (en)
JP (2) JP2015508791A (en)
KR (2) KR102027613B1 (en)
CN (3) CN104136008A (en)
BR (2) BR112014021391B1 (en)
CA (2) CA2865030C (en)
ES (1) ES2659466T3 (en)
IL (2) IL233759B (en)
IN (2) IN2014DN08089A (en)
MX (2) MX2014010445A (en)
NO (1) NO2819649T3 (en)
PL (1) PL2819649T3 (en)
PT (1) PT2819649T (en)
RU (2) RU2678319C2 (en)
WO (2) WO2013127727A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (en) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR101588247B1 (en) * 2013-04-17 2016-01-25 경희대학교 산학협력단 Composition for preventing or treating stroke or degenerative brain disease
EP3054940B1 (en) * 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
GB201402450D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
GB201402457D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Capsules containing high doses of phospholipids
GB201407345D0 (en) 2014-04-25 2014-06-11 Aker Biomarine As Krill Phospholipid compositions
MX2016014281A (en) 2014-05-22 2017-02-22 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies.
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
EP3232798A1 (en) 2014-12-19 2017-10-25 Aker Biomarine Antarctic AS Enhanced omega-3 formulations
CN107567331A (en) * 2015-03-31 2018-01-09 费森尤斯卡比德国有限公司 Emulsion for parenteral
GB201509606D0 (en) * 2015-06-03 2015-07-15 Anabio Technologies Ltd Microencapsulates containing stabilised marine-derived oil, and methods for production thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018011705A (en) 2016-04-01 2019-06-10 Therapeuticsmd Inc Steroid hormone pharmaceutical composition.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN105878184A (en) * 2016-04-26 2016-08-24 天津市中升挑战生物科技有限公司 Altrenogest nanometer emulsion and method for preparing same
HRP20250125T1 (en) * 2017-08-10 2025-03-28 The Children's Medical Center Corporation METHODS AND PREPARATIONS RELATED TO EMULSIONS CONTAINING FISH OIL AND/OR OMEGA-3 FATTY ACIDS
EP4076384B1 (en) 2019-12-20 2024-11-13 Fresenius Kabi Austria GmbH Method for manufacturing oil-in-water emulsions
JP2023521917A (en) * 2020-04-15 2023-05-25 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Stable diglyceride emulsions and methods for treating organ damage
US20240050391A1 (en) * 2020-12-07 2024-02-15 The Trustees Of Columbia University In The City Of New York Compositions and methods for neuroprotection in neonatal hypoxic-ischemic encephalopathy
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment
DE102023128848A1 (en) * 2023-10-20 2025-04-24 Sativari UG (haftungsbeschränkt) Liquid pharmaceutical formulation for intravenous, subcutaneous, or intramuscular administration of one or more cannabinoids
WO2025083197A1 (en) * 2023-10-20 2025-04-24 Sativari UG (haftungsbeschränkt) Liquid pharmaceutical formula for intravenous, subcutaneous or intramuscular application of one or more cannabinoids

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2738253A1 (en) 1977-08-25 1979-03-01 Dabisch Tipp Ex Tech BODY WITH REVERSIBLE TEMPERATURE-DEPENDENT TRANSPARENCY
DE2749265A1 (en) 1977-11-03 1979-05-10 Linde Ag METHOD FOR BIOLOGICAL WASTE WATER TREATMENT
JPS60258110A (en) 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk Progesterone emulsified parenteral solution injectable intravenously
US5560364A (en) 1995-05-12 1996-10-01 The Board Of Regents Of The University Of Nebraska Suspended ultra-sound induced microbubble cavitation imaging
US20100173876A1 (en) 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
EP1488785A1 (en) * 2003-06-18 2004-12-22 B. Braun Melsungen Ag Oil emulsion for postnatal substitution of hormones
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
JP5295755B2 (en) 2005-03-24 2013-09-18 エモリー ユニバーシティー Dosing regimen for the treatment of traumatic brain injury with progesterone
BRPI0613358A8 (en) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv polyunsaturated fat acids for the treatment of dementia and conditions related to pre-dementia
EP1973525B1 (en) 2005-12-05 2014-04-30 RBA Pharma Inc. Emulsion-containing medical articles
AR059012A1 (en) * 2006-01-13 2008-03-05 Aker Biomarine Asa EXTRACTS DERIVED FROM KRILL
JP5352961B2 (en) * 2006-03-28 2013-11-27 Jnc株式会社 Life-style related diseases prevention / treatment agents
CN101152186B (en) 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 Progesterone injection and method for preparing the same
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
RU2009145010A (en) 2009-12-04 2011-06-20 Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU) COMPOSITION OMEGA-3 AND OMEGA-6 POLYUNSATURATED FATTY ACIDS
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
US8895074B2 (en) * 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
CN102277237B (en) * 2011-06-20 2013-04-24 山东禹王制药有限公司 Preparation method of high-purity glyceride type fish oil

Also Published As

Publication number Publication date
BR112014021391A2 (en) 2017-06-20
MX2014010442A (en) 2014-10-13
ES2659466T3 (en) 2018-03-15
CN110251463A (en) 2019-09-20
NO2819649T3 (en) 2018-06-09
PL2819649T3 (en) 2018-06-29
CN104136007A (en) 2014-11-05
CA2865030A1 (en) 2013-09-06
BR112014021391B1 (en) 2022-07-26
CA2864945A1 (en) 2013-09-06
RU2678319C2 (en) 2019-01-28
MX2014010445A (en) 2014-10-13
PT2819649T (en) 2018-02-19
US20150011515A1 (en) 2015-01-08
KR20140131936A (en) 2014-11-14
BR112014021390A2 (en) 2019-09-24
CN104136008A (en) 2014-11-05
KR102027613B1 (en) 2019-10-01
WO2013127728A1 (en) 2013-09-06
KR20140131937A (en) 2014-11-14
JP2015508791A (en) 2015-03-23
RU2014138996A (en) 2016-04-20
EP2819649B1 (en) 2018-01-10
US9789122B2 (en) 2017-10-17
JP6169110B2 (en) 2017-07-26
CA2865030C (en) 2021-04-27
JP2015508792A (en) 2015-03-23
RU2014139008A (en) 2016-04-20
IL233760A0 (en) 2014-09-30
US20150018320A1 (en) 2015-01-15
MX356427B (en) 2018-05-29
IL233759A0 (en) 2014-09-30
WO2013127727A1 (en) 2013-09-06
IL233759B (en) 2019-01-31
EP2819649A1 (en) 2015-01-07
IN2014DN08088A (en) 2015-05-01
EP2819650A1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
IN2014DN08089A (en)
MX2011009507A (en) Omega-3 enriched fish oil-in-water parenteral nutrition emulsions.
NZ721036A (en) Lipid comprising long chain polyunsaturated fatty acids
NZ626699A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
MX349678B (en) PRODUCTION OF LONG CHAIN POLYINSATURATED FATTY ACIDS IN VEGETABLE CELLS.
HRP20200065T1 (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
PH12014500105A1 (en) Fatty acid compositions
NZ709083A (en) Eicosapentaenoic acid (epa) formulations
NZ613586A (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
FR2955459B1 (en) OIL COMPOSITION RICH IN MONOGLYCERIDES OF DHA
TW201613488A (en) Nutritional compositions containing oil blends and uses thereof
NZ716730A (en) Methods, compositions, and devices for supplying dietary fatty acid needs
RU2015148149A (en) CHILD MIXTURE WITH A LOW CONTENT OF MCFA IN CERTAIN PROPORTIONS AND RELATIVELY A HIGH CONTENT OF FATTY ACIDS AND ITS APPLICATION IN STIMULATION OF HEALTHY BECOMING OF COGNITIVE FUNCTION IN CHILDREN
BR112014013593A8 (en) dha retention during canola oil processing
HRP20171431T1 (en) THERAPY PARENTERAL APPLICATION OF WING OIL
UA111967C2 (en) HEALTHY FOOD PRODUCT CONTAINING FATTY FATTY ACIDS AND FATTING METHOD
EA201591680A1 (en) FATTY ACID MIXTURE (GLS, FATTY ACIDS GROUP) AND ITS APPLICATION FOR THE TREATMENT OF INFLAMMATORY PATHOLOGIES
PE20251289A1 (en) COMPOSITIONS OF POLYUNSATURATED FATTY ACIDS ENRICHED WITH DHA
MX2022005627A (en) LIPID THAT COMPRISES DOCOSAPENTAENOIC ACID.
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
MX358743B (en) Non-oleic triglyceride based, low viscosity, high flash point dielectric fluids.
WO2014137894A3 (en) Production of omega-3 fatty acids from pythium species
Dias et al. Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats
MY175186A (en) Glyceride composition
MX358901B (en) Triglyceride based, low viscosity, high flash point dielectric fluids.